Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03909425
Other study ID # PATP1032
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2, 2019
Est. completion date August 16, 2021

Study information

Verified date November 2023
Source Moorfields Eye Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment. The target population group is patients that have neovascular age-related macular degeneration and have had treatment with aflibercept for this condition. This is a single-site study and does not involve any masking or treatment allocation.


Description:

Treatment of this condition (neovascular age-related macular degeneration - nAMD) with aflibercept has transformed the outlook for patients with this sight-threatening disease. In clinical practice, eye doctors commonly use a "treat and extend" approach to treatment in which the interval between aflibercept injections is gradually increased once there is nAMD disease quiescence. It is uncertain about the ideal retinal imaging biomarkers doctors should use to define disease remission or inactivity; and therefore extend treatment intervals. Increased certainty of the ideal biomarker would also avoid stopping treatment too soon. The scan the investigators will be performing (OCTA imaging) detects blood flow within the choroidal neovascular membrane (CNV) - the immature blood vessel network which causes nAMD. This scan is therefore a potentially powerful way of determining if the disease is active or quiescent. Disease activity on this device can be defined as a blood flow pattern which suggests an active CNV or lesion growth. By better defining disease activity using OCTA, eye doctors would be more confident in continuing and defining a treatment plan for nAMD.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date August 16, 2021
Est. primary completion date August 16, 2021
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Patients over 50 years of age with a diagnosis of nAMD receiving anti-VEGF treatment with no signs of intra-or subretinal fluid on structural OCT imaging and with no macular haemorrhage after a minimum of three intravitreal injections - Visual acuity in the study eye of 35 Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score or better (6/60 or better) - Ability to understand the nature/purpose of the study and to provide informed consent - Any ocular condition which would lead to image artefact or poor OCT image quality - Ability to undergo retinal imaging Exclusion Criteria: - Patients with polypoidal choroidal vasculopathy or pachychoroid - Patients in whom imaging of the study eye leads to ungradable OCTA images. - Any condition which, in the investigators' opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule or other study conduct.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Moorfields Eye Hospital NHS Foundation Trust, 162 City Road London

Sponsors (1)

Lead Sponsor Collaborator
Moorfields Eye Hospital NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants treated nAMD Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks 18 Months
See also
  Status Clinical Trial Phase
Recruiting NCT04101877 - The Sahlgrenska Anti-VEGF Study Phase 2
Completed NCT03953079 - A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Phase 2
Terminated NCT03577899 - Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Completed NCT01926977 - Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Phase 1/Phase 2
Recruiting NCT00370539 - Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD Phase 3
Recruiting NCT03683251 - Extension Study for the Port Delivery System With Ranibizumab (Portal) Phase 3
Completed NCT03744767 - Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration Phase 2
Recruiting NCT04690556 - Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD Phase 3
Completed NCT05281042 - Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
Completed NCT03677934 - A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration Phase 3
Recruiting NCT03594461 - Intense Treatment Regimen With Intravitreal Aflibercept Injection Phase 1/Phase 2
Completed NCT05131646 - Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Completed NCT04537884 - Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Phase 1
Completed NCT03216538 - Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT04304755 - Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) Phase 2
Completed NCT01958918 - Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Phase 4
Active, not recruiting NCT01918878 - Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Phase 4
Completed NCT01712035 - Neovascular Age-related Macular Degeneration
Recruiting NCT03021785 - A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration Phase 1